Gilteritinib
In April 2018 , Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia ( AML ) . 
<triplet> FLT3 mutation <subj> acute myeloid leukemia <obj> genetic association <triplet> acute myeloid leukemia <subj> FLT3 mutation <obj> genetic association